| fibromyalgia |
026, 107 |
| metabolic syndrome |
026 |
| obesity |
026 |
| pain pressure threshold |
026 |
| anakinra |
146 |
| canakinumab |
146 |
| etanercept |
146 |
| juvenile idiopathic arthritis |
146 |
| tocilizumab |
146 |
| anxiety |
038 |
| fibromyalgia syndrome |
038 |
| nesfatin-1 |
038 |
| disease-modifying antirheumatic drug |
001 |
| functional status |
001 |
| psoriatic arthritis |
001 |
| quality of life |
001 |
| abatacept |
010 |
| arashi score |
010 |
| large joint |
010 |
| rheumatoid arthritis |
010, 063 |
| connective tissue diseases |
019 |
| diagnosis |
019 |
| interstitial lung disease |
019 |
| screening |
019 |
| vector |
019 |
| velcro crackles |
019 |
| juvenile systemic lupus erythematosus |
047 |
| lupus nephritis |
047 |
| nephritis activity |
047 |
| urinary alpha chain of the interleukin-2 receptor |
047 |
| cardiovascular disease risk |
063 |
| heart disease |
063 |
| knowledge of cardiovascular disease |
063 |
| fibrosis |
129 |
| immunoglobulin g4-related disease |
129 |
| lumbar vertebral involvement |
129 |
| ankylosing spondylitis |
056 |
| choroid thickness |
056 |
| infliximab |
056 |
| optical coherence tomography |
056 |
| retinal nerve fiber layer thickness |
056 |
| b-cell activating factor |
072 |
| biomarker |
072 |
| sarcoidosis |
072 |
| females |
120 |
| qualitative study |
120 |
| systemic lupus erythematosus |
120, 101, 089 |
| autoimmune disease |
101 |
| rheumatology |
101 |
| vitamin d |
101 |
| health perceptions |
089 |
| health-related quality of life |
089 |
| physical activity |
089 |
| physical capacity |
089 |
| depressive symptoms |
089 |
| axial spondyloarthritis |
080 |
| fluoroscopy |
080 |
| intraarticular injection |
080 |
| sacroiliac joint |
080 |
| sacroiliitis |
080 |
| carpal tunnel syndrome |
107 |
| electrodiagnosis |
107 |
| nerve compression syndrome |
107 |
| paresthesia |
107 |
| tarsal tunnel syndrome |
107 |
| breast pain index |
114 |
| mastalgia |
114 |
| myofascial pain syndrome |
114 |
